TABLE 1.
KEGG pathway analysis of proteins with significant phosphorylation change induced by miR‐193a‐3p overexpression
| KEGG pathway | Number of proteins | Phosphorylation change ratea (%) | P‐value | FDR | Proteins |
|---|---|---|---|---|---|
| AMPK signaling pathway | 14 | 44 | 2.18E‐08 | 2.70E‐05 | FKHRL1/FOXO3A, PDK1, CREB, LKB1, PPAR‐gamma, AKT1, mTOR, AMPK beta1, AKT1S1, ACC1, AMPK1, IRS‐1, SREBP‐1, 4E‐BP1 |
| VEGF signaling pathway | 11 | 42 | 1.44E‐08 | 1.78E‐05 | Caspase 9, FAK, PLCG1, c‐PLA2, PLCG2, Raf1, PKC alpha/beta II, MEK1, VEGFR2, BAD, AKT1 |
| PI3K‐AKT signaling pathway | 34 | 39 | 5.17E‐19 | 6.39E‐16 | Caspase 9, Raf1, PKC alpha/beta II, EGFR, NFkB‐p65, GSK3 beta, p27Kip1, LKB1, mTOR, SYK, ATF2, AMPK1, 4E‐BP1, BAD, IL‐2RA/CD25, FAK, SREBP‐1, FKHRL1/FOXO3A, CD19, MEK1, HSP90 co‐chaperone Cdc37, VEGFR2, PDK1, CREB, Integrin beta‐4, HSP90B, AKT1, p53, IRS‐1, 14‐3‐3 beta/zeta, NFkB‐p105/p50, Myc, S6 Ribosomal Protein, Cyclin D3 |
| ERBB signaling pathway | 19 | 35 | 1.70E‐16 | 2.78E‐13 | c‐Jun, FAK, HER2, Raf1, PKC alpha/beta II, Elk1, EGFR, MEK1, GSK3 beta, p27Kip1, AKT1, mTOR, MKK4/SEK1, PLCG1, PLCG2, STAT5B, 4E‐BP1, BAD, Myc |
| Cell cycle | 13 | 34 | 2.11E‐07 | 2.62E‐04 | SMC1, Chk2, GSK3 beta, Chk1, p27Kip1, p53, CDK1/CDC2, PLK1, 14‐3‐3 beta/zeta, HDAC2, Cyclin B1, Myc, Cyclin D3 |
| Focal adhesion | 22 | 34 | 1.15E‐12 | 1.42E‐09 | c‐Jun, FAK, HER2, Raf1, PKC alpha/beta II, Elk1, EGFR, MEK1, Vinculin, GSK3 beta, Ras‐GRF1, VEGFR2, PDK1, p130Cas, XIAP, VASP, Caveolin‐1, Integrin beta‐4, AKT1, Catenin beta, BAD, Cyclin D3 |
| mTOR signaling pathway | 10 | 33 | 1.30E‐07 | 1.61E‐04 | PKC alpha/beta II, AKT1S1, AMPK1, IRS‐1, 4E‐BP1, PDK1, LKB1, AKT1, S6 Ribosomal Protein, mTOR |
| HIF‐1 signaling pathway | 13 | 33 | 1.16E‐08 | 1.44E‐05 | HER2, PLCG1, PLCG2, PKC alpha/beta II, EGFR, MEK1, NFkB‐p65, 4E‐BP1, NFkB‐p105/p50, p27Kip1, AKT1, S6 Ribosomal Protein, mTOR |
| MAPK signaling pathway | 24 | 32 | 9.43E‐13 | 1.17E‐09 | c‐Jun, MEF2C, Tau, Raf1, MSK1, c‐PLA2, PKC alpha/beta II, EGFR, Elk1, NFkB‐p65, MEK1, PKA CAT, Ras‐GRF1, AKT1, p53, MKP1, MKP2, MKK4/SEK1, Arrestin‐1, FAS, Stathmin 1, ATF2, NFkB‐p105/p50, Myc |
| TNF signaling pathway | 11 | 30 | 3.20E‐06 | 3.96E‐03 | c‐Jun, MKK4/SEK1, FAS, MSK1, NFkB‐p65, ATF2, MEK1, NFkB‐p105/p50, CREB, AKT1, JunD |
| cAMP signaling pathway | 14 | 29 | 5.53E‐06 | 6.84E‐03 | c‐Jun, NMDAR1, Raf1, NFkB‐p65, MEK1, PKA CAT, ATPase, CREB, RyR2, AKT1, PLD1, BAD, NFkB‐p105/p50, DARPP‐32 |
| Rap1 signaling pathway | 15 | 27 | 1.94E‐06 | 2.41E‐03 | NMDAR1, Raf1, PKC alpha/beta II, EGFR, PLC beta3, MEK1, VEGFR2, p130Cas, VASP, LAT, AKT1, Catenin beta, PKD2, PLCG1, PKD1/PKC mu |
| Ras signaling pathway | 18 | 27 | 2.29E‐08 | 2.83E‐05 | NMDAR1, c‐PLA2, Raf1, PKC alpha/beta II, Elk1, EGFR, NFkB‐p65, MEK1, PKA CAT, Ras‐GRF1, VEGFR2, LAT, AKT1, PLCG1, PLCG2, PLD1, BAD, NFkB‐p105/p50 |
| FoxO signaling pathway | 13 | 25 | 4.96E‐07 | 6.13E‐04 | Raf1, EGFR, FKHRL1/FOXO3A, MEK1, PDK1, LKB1, p27Kip1, AKT1, AMPK beta1, PLK1, AMPK1, IRS‐1, CyclinB1 |
Proteins with altered phosphorylation rate (FC < 0.75 or FC > 1.33) were subjected to KEGG pathway analysis.
Abbreviations: FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.
a
Phosphorylation change rate means percentage of proteins with phosphorylation change, which was calculated by dividing proteins with phosphorylation change by all analyzed proteins in each pathway.